Gemini Therapeutics, Inc. announced a corporate restructuring, including several executive officer transitions, to prioritize assets and focus on initiating and executing GEM103’s resource-intensive pivotal trial in geographic atrophy (GA). As part of the Company’s restructuring, Gemini’s research and non-clinical programs will be ceased, including activities associated with gene therapy programs and translational research on Complement Factor H (CFH) and Complement Factor I (CFI). The Company will accordingly reduce employee headcount by 20% compared to planned 2021 year-end headcount, including the elimination or transition of certain leadership positions. Georges Gemayel, Ph.D., Gemini’s Chair of the Board, will transition to serve as Executive Chair to further support and partner with the management team through these transitions. Avner Ingerman, M.D., has been promoted to serve as Gemini’s Chief Development Officer, taking on strategic development functions and oversight including regulatory affairs and medical affairs responsibilities. Brian Piekos, Chief Financial Officer, will now additionally serve as Chief Business Officer and assumes additional leadership responsibilities for various functions including manufacturing, business development, and investor relations. Marissa Volpe and Patrick Truesdell will join the Company as Gemini’s Vice President of Clinical Operations and Vice President of Finance & Controller, respectively. The roles of Chief Scientific Officer and Chief People Officer, held by Walter Strapps, Ph.D. and Precillia Redmond, respectively, will be eliminated by the end of the year.